🔗 Visit the ClinicalTrials.gov page for NCT00289016
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Talimogene laherparepvec (T-VEC) for the treatment of advanced melanoma. | Immunotherapy | 2015 | 0.83 |
| 2 | Assessment of current virotherapeutic application schemes: "hit hard and early" versus "killing softly"? | Mol Ther Oncolytics | 2015 | 0.77 |
| 3 | New clinical advances in immunotherapy for the treatment of solid tumours. | Immunology | 2015 | 0.76 |
| 4 | Immunotherapy in the management of melanoma: current status. | Immunotargets Ther | 2013 | 0.75 |